Clinical Scorecard: GETAID: Four Decades of Advancements in Inflammatory Bowel Disease Research

At a Glance

Key Highlights

• GETAID was founded in 1983 as an international, multicenter French-speaking group dedicated to clinical research in IBD.
• Development and validation of the Crohn’s Disease Endoscopic Index of Severity (CDEIS) to objectively quantify endoscopic disease severity.
• Over 40 years, GETAID has published more than 120 original peer-reviewed articles, advancing knowledge in IBD treatment and management.

Guideline-Based Recommendations

Diagnosis

• Use of endoscopy with standardized quantification of disease severity (e.g., CDEIS) to assess Crohn’s disease activity.

Management

• Standard induction treatment with steroids (e.g., prednisolone) for Crohn’s disease flares.
• Clinical trials have not supported extending steroid treatment based solely on persistent severe endoscopic lesions in clinical remission.

Monitoring & Follow-up

• Regular clinical, biological, and endoscopic evaluation to monitor disease activity and treatment response.

Risks

• Recognition of discrepancies between clinical remission and persistent endoscopic lesions, highlighting the need for comprehensive assessment.

Patient & Prescribing Data

Patients with Crohn’s disease experiencing flare-ups and clinical remission phases.

Prednisolone is effective for inducing remission; however, prolonging steroid therapy based on endoscopic severity alone has not demonstrated additional benefit.

Clinical Best Practices

• Collaborative multicenter clinical trials to address relevant clinical questions in IBD.
• Use of validated endoscopic indices (CDEIS) for objective disease severity assessment.
• Integration of clinical, biological, and endoscopic data for comprehensive patient management.

References

• GETAID official publications and history